Auto Amazon Links: No products found.
A recent clinical trial has revealed a pill that nearly doubles the survival time of patients suffering from advanced pancreatic cancer, a development experts are calling a major breakthrough. The medication, named daraxonrasib, targets a mutation in the KRAS gene, which is present in over 90% of pancreatic tumors and plays a critical role in the progression of the disease. By inhibiting this gene, the drug effectively slows down cancer growth and spread.
This international study enrolled 500 participants from North America, Europe, and Asia to compare the effects of daraxonrasib against standard chemotherapy. Findings demonstrated that patients treated with chemotherapy survived an average of 6.6 months, while those receiving daraxonrasib lived for about 13.2 months on average. Furthermore, daraxonrasib was associated with fewer and less severe side effects than traditional chemotherapy, with 43.6% of participants experiencing serious adverse reactions compared to 57.5% in the chemotherapy group.
Pancreatic cancer remains one of the most challenging cancers to diagnose and treat, often being detected only at advanced stages. It carries the highest mortality rate among major cancers, with more than half of patients dying within three months of diagnosis. In the UK alone, there are roughly 11,500 new cases annually and approximately 10,200 deaths, highlighting the urgent need for effective treatment options. Rachna Shroff, chief of the division of haematology/oncology at the University of Arizona Cancer Centre, emphasized the significance of this advancement, stating, “These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation.”
The trial was led by American researchers and involved 248 patients receiving daraxonrasib and 252 undergoing chemotherapy. Most of the participants had tumors harboring specific KRAS mutations. Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the findings as “some of the most exciting developments we have seen in pancreatic cancer for a very long time,” adding, “More time with those we love most is truly priceless. We must do everything possible to ensure the most promising new treatments are available here in the UK.
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.